Panavance Therapeutics Inc. is a US, clinical-stage pharmaceutical company established in 2021 by the Swiss-based Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie. Panavance is focused on advancing the development of GP-2250, a novel oncology therapeutic intended to improve outcomes and quality of life for patients with cancer.

With its highly capable team and strong academic and industry partnerships, Panavance is pursuing a rigorous program to bring GP-2250 to patients around the world.

Life Sciences

Pharmaceutical

Therapeutics

Panavance Therapeutics Inc.

Panavance Therapeutics Inc.'s headquarters in Berwyn, United States

Robert Hrubiec

Ben Steinmetz

José Iglesias

Tom Hess

Carol Gorman

Kathryn Martin

The Leadership Team at Panavance Therapeutics Inc. is responsible for steering the company’s strategic direction, overseeing clinical and commercial operations, ensuring financial stability, and fostering key academic and industry partnerships to advance the development and global distribution of the novel oncology therapeutic, GP-2250.

Leadership Team

The Scientific and Research Team at Panavance Therapeutics Inc. is responsible for driving the advancement of GP-2250. Comprising experts in CMC (Chemistry, Manufacturing, and Controls), non-clinical research, pharmacology, and regulatory communications, the team conducts rigorous research, ensures quality control, navigates regulatory landscapes, and collaborates with academic and industry partners to bring innovative oncology therapies to patients globally.

Panavance Therapeutics Inc.

Org chart

Teams

Leadership Team

Scientific and Research Team

Offices

Panavance Therapeutics Inc.

Org chart

Teams

Leadership Team

Scientific and Research Team

Offices

Related companies